

Immunosuppressants (for SOT) Treatment Selector

Charts reviewed October 2019. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/ F/TAF	DTG	EVG/c/ F/TAF	EVG/c/ F/TDF	RAL	ABC	FTC or 3TC	F/TAF	TDF	ZDV	
Corticosteroids																						
Prednisone	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↑ ^a	↔	↓20%	↓	↓	↔	↔	↔	↔	↑11%	↑ ^a	↑ ^a	↔	↔	↔	↔	↔	
Antimetabolites																						
Azathioprine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ ^b	
Mycophenolate	↔	↓ ^c	↔	↓ ^c	↓ ^c	↔	↓ ^c	↔	↓13%	↔	↔	↔	↔	↔	↔	↑↑ ^d	↔	↓?	↔	↔	↑↑ ^e	↓?
Calcineurin inhibitors																						
Ciclosporin	↑ ^c	↑ ^c	↑ ^c	↑ ^c	↑ ^c	↑	↓ ^c	↓ ^c	↓ ^c	↑	↑	↑ ^g	↔	↑ ^c	↑ ^c	↔	↔	↔	↔	↑ ^h	↑ ^e	↔
Tacrolimus	↑ ^c	↑ ^c	↑ ^c	↑ ^c	↑ ^c	↓ ^c	↓ ^c	↓ ^c	↓ ^c	↔	↔	↔	↔	↑ ^c	↑ ^c	↔	↔	↔	↔	↔	↔ ^e	↔
mTOR inhibitors																						
Everolimus	↑	↑	↑	↑	↑	↔	↓ ^c	↓ ^c	↓ ^c	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔	↔
Sirolimus	↑	↑	↑	↑	↑	↓ ^c	↓ ^c	↓ ^c	↓ ^c	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔ ^e	↔
Other																						
Anti-thymocyte globulin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ ^b	↔ ^b	↔	↔	↔	↔	↔	↔	↔
Basiliximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Belatacept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the immunosuppressant
- ↓ Potential decreased exposure of the immunosuppressant
- ↔ No significant effect
- ↑↑ Potential increased exposure of HIV drug
- ↓↓ Potential decreased exposure of HIV drug

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

Notes

- a Risk of elevated corticosteroid levels, Cushing's syndrome and adrenal suppression.
- b Potential additive haematotoxicity.
- c TDM of immunosuppressant is recommended.
- d Concentrations of tenofovir-DF may increase, but no effect on elvitegravir, cobicistat or emtricitabine is expected. Monitor renal function.
- = Monitor renal function.
- g Coadministration may increase concentrations of bictegravir and tenofovir alafenamide; no effect on emtricitabine is expected.
- h Coadministration may increase concentrations of tenofovir alafenamide; no effect on emtricitabine is expected.